Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
67.20    -0.80 (-1.18%)
Bid:
67.10
Ask:
67.30
Spread: 0.20 (0.298%)
Market Cap: £593.66m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Board changes

6 Oct 2021 07:00

RNS Number : 1257O
IP Group PLC
06 October 2021
 

FOR RELEASE ON

06 October 2021

 

 

IP Group plc - Board changes

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), the developer of intellectual property-based businesses, announces that following the successful flotation of the Group's largest holding, Oxford Nanopore Technologies plc, Alan Aubrey, Chief Executive Officer, and Mike Townend, Chief Investment Officer, are retiring and stepping down from the IP Group Board from today.

 

The Board is delighted to announce that Greg Smith, Chief Financial Officer, will succeed Alan as Chief Executive Officer and David Baynes, the Group's Chief Operating Officer, will take on executive responsibility for finance and becomes Chief Financial and Operating Officer.

 

To facilitate an orderly handover and transition, both Alan and Mike will remain as employees, serving their six-month notice periods until 06 April 2022 and as consultants for a minimum of 12 months from 07 April 2022.

 

As referenced in the Group's 2020 Annual Report & Accounts, the Nomination Committee used an external executive search and leadership consultancy to assist in identifying and assessing candidates both internally and externally as part of succession planning. The Committee deferred finalising its recommendation to align the final decision with anticipated events in the portfolio, such as the potential Oxford Nanopore flotation, and to ensure continued stability for the Group during the pandemic. Following the flotation of Oxford Nanopore and the easing of COVID-19 restrictions, the Committee reconvened and its recommendations were unanimously accepted by the Board.

 

Sir Douglas Flint, Chairman of IP Group, said: "On behalf of the Board and the wider IP Group family, I would like to thank both Alan and Mike for the transformational contributions they have made to IP Group over the past 16 and 14 years respectively. During Alan's tenure as CEO, the value of the portfolio has increased more than 28-fold to over £1.2bn* and has produced several companies worth more than £1bn. We are delighted that Greg will step into the role of CEO and lead the Group in its next phase. We are also pleased that Alan and Mike will continue with the Group in a consulting capacity so that the Group can continue to call on their significant experience in the sector. Greg has more than 20 years' experience in financial services, having been in the role of CFO for more than ten years and with IP Group for more than thirteen years. He has played a central role in developing and executing the Group's growth strategy which made him the obvious and unanimous choice to succeed Alan."

 

Alan Aubrey said: "Following the successful flotation of Oxford Nanopore Technologies on the London Stock Exchange, this felt a natural moment to step back. It has been a privilege and an honour to build and lead the team at IP Group and I am proud of all that has been achieved during this time. The Group is in great shape with a strong balance sheet, a portfolio of exciting growth technology companies and opportunities and I am confident that it will go from strength to strength under Greg's leadership. I look forward to continuing working with IP Group in a different capacity going forward and continuing to support the team in the future."

 

Commenting on his new role, Greg Smith said: "It is an exciting time to be taking on the role of CEO at IP Group. The Group benefits from a very strong financial position, a portfolio of growth technology companies and an excellent pipeline. I am looking forward to building on recent successes and I am confident that IP Group will continue to deliver world-changing businesses that have real impact as well as deliver value for all stakeholders."

 

The Group will consult with shareholders this Autumn on remuneration arrangements for the CEO and CFOO as part of the regular triennial review of Directors remuneration policy. IP Group will continue to align the interests of the Executive team with those of shareholders and other stakeholders and will discuss the optimum structure and level required to achieve this as part of the forthcoming consultation. Remuneration arrangements for the departing executive directors will be published on the Company's website and included in the 2021 Annual Report in the usual way.

There are no further updates required under Listing Rule 9.6.13 as a result of this change of roles.

*As at 30 June 2021.

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAVELFBFBLEFBD
Date   Source Headline
2nd Sep 201911:48 amRNSHolding(s) in Company
19th Aug 20192:25 pmRNSHolding(s) in Company
13th Aug 20193:31 pmRNSHolding(s) in Company
1st Aug 20194:19 pmRNSHolding(s) in Company
15th Jul 20197:09 amRNSCeres Power signs collaboration with Doosan
15th Jul 20197:00 amRNSIstesso announces positive P2a study of MBS2320
9th Jul 20191:35 pmRNSHolding(s) in Company
9th Jul 201910:50 amRNSHolding(s) in Company
13th Jun 20197:00 amRNSAppointment of Non-executive Director
7th Jun 20195:12 pmRNSHolding(s) in Company
7th Jun 20191:19 pmRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
28th May 20196:04 pmRNSHolding(s) in Company
28th May 20195:42 pmRNSResult of AGM
28th May 201911:13 amRNSAppointment of Caroline Brown as NED
16th May 20196:21 pmRNSWithdrawal of resolution from 2019 AGM
3rd May 20199:38 amRNSAppointment of corporate broker
26th Apr 20196:23 pmRNSLTIP & DBSP awards; DBSP option exercise
18th Apr 20192:54 pmRNSAnnual Financial Report
15th Apr 201911:55 amRNSHolding(s) in Company
11th Apr 20197:12 amRNSDiurnal positive advice from EMA for Chronocort
26th Mar 20197:00 amRNSFinal Results
19th Mar 20193:32 pmRNSHolding(s) in Company
8th Mar 20192:20 pmRNSHolding(s) in Company
5th Mar 20195:54 pmRNSHolding(s) in Company
12th Feb 20199:36 amRNSDirector Declaration
12th Feb 20199:03 amRNSFLF aims for fusion by mid 2019 on Machine 3
28th Jan 20197:00 amRNSPortfolio co Featurespace completes £25m round
18th Jan 20191:25 pmRNSHolding(s) in Company
3rd Jan 20198:56 amRNSHolding(s) in Company
11th Dec 20187:00 amRNSWaveOptics completes £20.0m funding round
10th Dec 20187:05 amRNSAvacta signs deal with LG Chem worth up to $310m
4th Dec 20185:49 pmRNSPortfolio co Ceres finalises deal with Weichai
3rd Dec 20187:00 amRNSUltrahaptics completes £35.0m funding round
31st Oct 20185:52 pmRNSDirector Declaration
18th Oct 20182:00 pmRNSAmgen invests £50m in Oxford Nanopore Technologies
15th Oct 20187:00 amRNSPortfolio co Garrison completes £22.9m financing
8th Oct 20187:07 amRNSPortfolio co Diurnal headline data for Chronocort
19th Sep 20189:51 amRNSDirector/PDMR Shareholding
17th Sep 20184:58 pmRNSDirector/PDMR Shareholding
17th Sep 20184:38 pmRNSDirector/PDMR Shareholding
17th Sep 201812:12 pmRNSDirector/PDMR Shareholding
17th Sep 20187:00 amRNSAppointment of Chairman; Board changes
31st Aug 20189:55 amRNSHolding(s) in Company
30th Aug 20187:00 amRNSGenomics announces Vertex leads £25m financing
29th Aug 20186:29 pmRNSIP Group plc -SAYE scheme
21st Aug 20187:06 amRNSCeres signs agreement with Bosch; £9m investment
10th Aug 20187:11 amRNSArtios Pharma completes £65m financing
31st Jul 20188:40 amRNSTR-1: NOTIFICATION
25th Jul 20187:00 amRNSHalf-yearly results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.